NEW YORK – Aytu BioScience said on Thursday it has reached a definitive deal with Biolidics to exclusively distribute that firm's coronavirus serology test in the US.
Under the terms of the deal, Englewood, California-based Aytu has committed to purchasing at least 1.25 million of Biolidics' COVID-19 IgG/IgM Rapid Tests within the first three months of the deal, including 500,000 tests in the first business day after the signing of the agreement.
Further details were not disclosed.
Singapore-based Biolidics recently received provisional authorization in Singapore to sell the test. Aytu will work with Biolidics and lead the US clinical trials processes with an eye at obtaining US Food and Drug Administration 510(k) clearance for the test, Aytu said.
Last month, Aytu announced it exclusively licensed the US distribution rights for a point-of-care SARS-Cov-2 immunoassay developed by China's Zhejiang Orient Gene Biotech.